Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (400)	6/2/1999 12:41:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Thanks, Mike, for the pointer. Good stuff, although I don't agree at all with a focus on antisense. And..... Malvern, Pa.-based Centocor is one of biotech's Comeback Kids. It stumbled badly in 1993 when its flagship sepsis drug, the monoclonal antibody Centoxin, failed in advanced clinical trials. The disaster forced Centocor to lay off most of its employees and cast a pall on the entire biotech industry. Pundits wrote off the once-hyped "magic bullet" monoclonal technology. I'm tired of this crap. HA-1A (Centoxin) didn't have squat to do with sepsis, and it should never have been tested in humans.